• Dec 18, 2013 | Webinar

    New Directions in Therapeutics of Rare Bone Diseases: X-Linked Hypophosphatemia (XLH) and Hypophosphatasia (HPP)

    Erik Imel, M.D., Michael P. Whyte, M.D.
    Rare Bone Diseases

    There have been advancements in our understanding of the mechanisms underlying a variety of rare bone diseases that have implications for development of novel treatments. The purpose of this webinar is to provide an update concerning new and exciting clinical strategies for the medical treatment of two rare bone diseases: XLH and HPP.

    Learning Objectives:

    • Understand the pathways targeted by new treatment strategies being pursued in XLH and HPP.
    • Understand the main findings from early phase clinical studies of these two diseases.

    Supported by an education donation provided by Alexion Pharmaceuticals

    Length: 60 minutes

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Policies and Procedures for more details